吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。

The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.

youdao

对124名法国患者的进一步研究提示，运用该模型，认为无风险的患者中位生存期为378天，有风险的只有90天。

Study of a further 124 French patients showed that those deemed at good risk using the model, had a median survival of 378 days, compared to 90 days in the poor risk group.

youdao

在治疗结束时，蛋白酶体水平升高患者的中位生存期是30.2个月。蛋白酶体水平恢复正常的患者没有观察到终点事件。

Median survival at the end of treatment was 30.2 months in patients with elevated levels. This point was not reached in patients with normalized levels.

youdao